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Abstract
Background: Gut ischemia/reperfusion (I/R) injury is a serious condition in intensive care patients. Activation of immune
cells adjacent to the huge endothelial cell surface area of the intestinal microvasculature produces initially local and then
systemic inflammatory responses. Stimulation of the vagus nerve can rapidly attenuate systemic inflammatory responses
through inhibiting the activation of macrophages and endothelial cells. Ghrelin, a novel orexigenic hormone, is produced
predominately in the gastrointestinal system. Ghrelin receptors are expressed at a high density in the dorsal vagal complex
of the brain stem. In this study, we investigated the regulation of the cholinergic anti-inflammatory pathway by the novel
gastrointestinal hormone, ghrelin, after gut I/R.
Methods and Findings: Gut ischemia was induced by placing a microvascular clip across the superior mesenteric artery for
90 min in male adult rats. Our results showed that ghrelin levels were significantly reduced after gut I/R and that ghrelin
administration inhibited pro-inflammatory cytokine release, reduced neutrophil infiltration, ameliorated intestinal barrier
dysfunction, attenuated organ injury, and improved survival after gut I/R. Administration of a specific ghrelin receptor
antagonist worsened gut I/R-induced organ injury and mortality. To determine whether ghrelin’s beneficial effects after gut
I/R require the intact vagus nerve, vagotomy was performed in sham and gut I/R animals immediately prior to the induction
of gut ischemia. Our result showed that vagotomy completely eliminated ghrelin’s beneficial effect after gut I/R. To further
confirm that ghrelin’s beneficial effects after gut I/R are mediated through the central nervous system, intracerebroven-
tricular administration of ghrelin was performed at the beginning of reperfusion after 90-min gut ischemia. Our result
showed that intracerebroventricular injection of ghrelin also protected the rats from gut I/R injury.
Conclusions: These findings suggest that ghrelin attenuates excessive inflammation and reduces organ injury after gut I/R
through activation of the cholinergic anti-inflammatory pathway.
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Introduction
Acute mesenteric ischemia is an abdominal emergency with a
mortality rate of up to 60–80% [1,2]. The intestinal mucosa is
extremely susceptible to ischemia/reperfusion (I/R) injury. Even
short periods of ischemia can induce the systemic production of
various inflammatory mediators and activates leukocytes, which
may lead to remote organ injury and subsequent mortality. The
vagus nerve has been shown to convey the immunologic state of
the gastrointestinal tract to the brain [3]. Activation of the vagus
nerve during systemic stress confers a protective advantage to the
host by restraining a potentially adverse peripheral immune
response. This physiological mechanism, termed the cholinergic
anti-inflammatory pathway, modulates host inflammatory re-
sponses via cholinergic mediators or by electrical stimulation of
the vagus nerve [4–6].
Ghrelin, an orexigenic hormone, was first identified in 1999 as
an endogenous ligand for the growth hormone secretagogue
receptor type 1a (GHSR-1a, i.e., ghrelin receptor) [7]. Ghrelin is
found throughout the gastrointestinal tract [8]. In addition to its
growth hormone-releasing properties [9], ghrelin has now been
proved to possess other endocrine and non-endocrine activities
reflecting central and peripheral GHSR-1a distribution [10,11].
Administration of ghrelin is beneficial following heart failure or
cardiac ischemia/reperfusion injury [12,13]. However, the precise
mechanism responsible for these beneficial effects remains largely
unknown. Our recent study has demonstrated that ghrelin’s direct
effect on inflammatory cytokine release from macrophages is
negligible [14]. Since intracerebroventricular (ICV) injection of
ghrelin stimulates the efferent vagus nerve [15], it has been
postulated that the anti-inflammatory property of ghrelin is
mediated through vagus nerve stimulation [11]. However, it
remains unknown whether ghrelin has any protective effects on
gut I/R-induced local and remote organ injury and, if so, the
potential mechanism responsible for it. This study was conducted
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e2026to test the hypothesis that ghrelin attenuates gut I/R-induced local
and remote organ injury and mortality through the activation of
the cholinergic anti-inflammatory pathway.
Results
Ghrelin levels decrease after gut I/R
As shown in Figure 1, plasma levels of ghrelin in sham operated
animals were 14.6 fmol/ml. At the end of 90 min ischemia,
plasma levels of ghrelin decreased by 73% (P,0.05). A slight
further decrease in plasma levels of ghrelin was found at 2 h after
reperfusion. However, there was no statistically significant
difference in plasma levels of ghrelin between ischemia alone
and I/R animals.
Ghrelin inhibits proinflammatory responses after gut I/R
As indicated in Figure 2A, serum levels of TNF-a increased by
4.7 fold at 2 h after gut I/R (P,0.05). Treatment with ghrelin
reduced serum TNF-a levels by 33% in gut I/R animals (P,0.05,
Fig. 2A). Similarly, serum levels of IL-6 increased by 22 fold 2 h
after gut I/R (P,0.05, Fig. 2B). Ghrelin treatment decreased them
by 62% (P,0.05), and there was no significant difference in serum
IL-6 levels between sham-operated and ghrelin treated gut I/R
animals (Fig. 2B). The level of myeloperoxidase (MPO) activity
is an indicator of neutrophil infiltration. As demonstrated in
Figures 3A-B, gut I/R induced a significant increase in intestinal
and pulmonary MPO activities in vehicle-treated rats as compared
with sham animals. Treatment with ghrelin significantly inhibited
the increase in both intestinal (Fig. 3A) and pulmonary (Fig. 3B)
MPO activities after gut I/R (P,0.05). These results show that
ghrelin downregulates proinflammatory cytokines and attenuates
the influx of neutrophils into the gut and lungs after gut I/R.
Ghrelin ameliorates intestinal barrier dysfunction after
gut I/R
Intestinal barrier dysfunction, manifested by increased mucosal
permeability to hydrophilic macromolecules and/or increased
bacterial translocation to mesenteric lymph nodes, occurs
following gut I/R [16]. As indicated in Figure 4A, ileal mucosal
permeability to the fluorescent macromolecule, FD4, was
significantly increased at 2 h after reperfusion in vehicle treated
animals as compared with sham controls (P,0.05). Similarly,
bacterial translocation to mesenteric lymph nodes was minimal in
the sham group, but was extensive in the gut I/R vehicle treated
group (P,0.05, Fig. 4B). Treatment with ghrelin at the time of
reperfusion, however, significantly ameliorated the development of
both ileal mucosal hyperpermeability and bacterial translocation.
Ghrelin attenuates organ injury after gut I/R
Compared with sham operated animals, serum levels of lactate
were more than doubled at 2 h after gut I/R in vehicle treated
animals (P,0.05, Fig. 5A). Ghrelin treatment significantly reduced
serum levels of lactate by 48% (P,0.05; Fig. 5A). As shown in
Figures 5B–C, rats subjected to gut I/R had a significant increase
in gut and lung water content as compared with sham-operated
animals (P,0.05). When I/R animals were treated with ghrelin,
the water content of the gut (Fig. 5B) and lungs (Fig. 5C) was
Figure 1. Alterations in plasma levels of ghrelin at the end of
90-min gut ischemia (Ischemia), 2 h reperfusion after ischemia
(Ischemia/reperfusion), or sham operation (Sham). Data are
presented as means6SE (n=5–6) and compared by one-way ANOVA
and Student-Newman-Keuls test: * P,0.05 versus Sham group.
doi:10.1371/journal.pone.0002026.g001
Figure 2. Alterations in serum levels of TNF-a (A) and IL-6 (B) in
sham-operated animals (Sham) and ischemia/reperfusion ani-
mals treated with normal saline (Vehicle) or ghrelin (Ghrelin) at
1.5 h after the completion of treatment (i.e., 2 h after
reperfusion). Data are presented as means6SE (n=6/group) and
compared by one-way analysis of variance (ANOVA) and Student-
Newman-Keuls test: *P,0.05 versus Sham group; #P,0.05 versus I/
R+Vehicle group.
doi:10.1371/journal.pone.0002026.g002
Figure 3. Alterations in intestinal (A) and pulmonary (B) MPO
activities in sham-operated animals (Sham) and ischemia/
reperfusion animals treated with normal saline (Vehicle) or
ghrelin (Ghrelin) at 1.5 h after the completion of treatment
(i.e., 2 h after reperfusion). Data are presented as means6SE (n=5–
6) and compared by one-way ANOVA and Student-Newman-Keuls test:
* P,0.05 versus Sham group; # P,0.05 versus Vehicle group.
doi:10.1371/journal.pone.0002026.g003
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water content between sham-operated and I/R ghrelin treated
animals. In terms of the histopathological changes, mucosal
destruction, loss of villi and epithelial cells, hemorrhage, and
infiltration of inflammatory cells were observed microscopically in
the rat intestine after I/R (Fig. 6B) as compared with sham
controls (Fig. 6A). Treatment with ghrelin dramatically improved
these microscopic alterations (Fig. 6C). Similarly, lung injury
characterized by disruption of lung architecture, extravasation of
red blood cells, and accumulation of inflammatory cells was
presented in I/R-vehicle treated animals (Fig. 6E). Ghrelin treated
rats revealed a marked reduction in infiltrated inflammatory cells
and improvement of lung architecture (Fig. 6F).
Ghrelin improves survival after gut I/R
The survival rate after gut I/R with vehicle administration was
50% at day 1 and decreased to 41.6% at days 2–10 (Fig. 7).
Treatment with ghrelin, however, improved the survival rate to
83.3%, which was significantly higher than that in the gut I/R
vehicle treated animals (P,0.05, Fig. 7).
Figure 5. Alterations in serum levels of lactate (A), gut (B) and
lung (C) water content in sham-operated animals (Sham) and
ischemia/reperfusion animals treated with normal saline
(Vehicle) or ghrelin (Ghrelin) at 1.5 h after the completion of
treatment (i.e., 2 h after reperfusion). Data are presented as
means6SE (n=5–6) and compared by one-way ANOVA and Student-
Newman-Keuls test: * P,0.05 versus Sham group; # P,0.05 versus
Vehicle group.
doi:10.1371/journal.pone.0002026.g005
Figure 4. Alterations in intestinal mucosal permeability (A) to
fluorescein isothiocyanate dextran with a molecular weight of
4000 Da (FD4) and bacterial translocation to mesenteric lymph
nodes (B) in sham-operated animals (Sham) and ischemia/
reperfusion animals treated with normal saline (Vehicle) or
ghrelin (Ghrelin) at 1.5 h after the completion of treatment
(i.e., 2 h after reperfusion). Data are presented as means6SE (n=6),
and compared by one-way ANOVA and Student-Newman-Keuls test: *
P,0.05 versus Sham group; # P,0.05 versus Vehicle group.
doi:10.1371/journal.pone.0002026.g004
Figure 6. Alterations in morphologic photomicrography of the small intestine and lungs. A, a photomicrograph of a small intestinal
section from a sham-operated rat; B, a photomicrograph of a small intestinal section from an I/R rat at 2 h after gut ischemia-reperfusion treated with
vehicle; C, a photomicrograph of a small intestinal section from an I/R rat at 2 h after gut ischemia-reperfusion treated with ghrelin; D,a
photomicrography of a pulmonary section from a sham-operated rat. E, a photomicrography of lung section from an I/R rat at 2 h after gut ischemia-
reperfusion treated with vehicle; F, a photomicrography of lung section from an I/R rat at 2 h after gut ischemia-reperfusion treated with ghrelin.
Original magnification, 6200.
doi:10.1371/journal.pone.0002026.g006
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increases mortality after gut I/R
To further define the role of ghrelin deficiency in gut I/R injury,
[D-Arg
1 D-Phe
5 D-Trp
7, 9 Leu
11]-substance P was administered to
gut I/R animals. As shown in Figures 8A–B, neutrophil infiltration
was further increased after [D-Arg
1 D-Phe
5 D-Trp
7, 9 Leu
11]-
substance P administration in gut I/R animals as demonstrated by
elevated levels of MPO activities in both gut and lungs as compared
withthoseingutI/Rvehicle-treatedanimals(P,0.05).Similarly,[D-
Arg
1 D-Phe
5 D-Trp
7, 9 Leu
11]-substance P further increased serum
levelsoflactate by 65%(P,0.05, Fig.8C). Mostimportantly,the 10-
day survival rate after gut I/R was decreased to 8.3% by [D-Arg
1 D-
Phe
5D-Trp
7, 9Leu
11]-substancePadministration(P,0.05,Fig.8D).
Ghrelin’s beneficial effects after gut I/R require the intact
vagus nerve
To determine whether ghrelin’s beneficial effects after gut I/R
require the intact vagus nerve, vagotomy was performed in sham
and gut I/R animals immediately prior to the induction of gut
ischemia as we described recently [14]. As indicated in Figures 9A–
B, vagotomy completely eliminates the effect of this agent on
serum levels of TNF-a and lactate. Similarly, ghrelin’s effects on
neutrophil infiltration in the gut (Fig. 9C) and intestinal barrier
dysfunction (Fig. 9D) after gut I/R are also completely abolished
by vagotomy. Thus, ghrelin’s beneficial effects after gut I/R
require the intact vagus nerve.
Figure 7. Alterations in the survival rate at 10 days after gut
ischemia/reperfusion with normal saline treatment (Vehicle)
and gut ischemia/reperfusion with ghrelin treatment (Ghrelin).
Ghrelin (12 nmol/kg BW), or vehicle (1-ml normal saline) was
administered intravenously over a period of 30 min to animals that
underwent 90 min gut ischemia immediately after removing the
microvascular clip. The animals were then allowed food and water ad
libitum and were monitored for 10 days to record survival. There were
12 animals in each group. The survival rate was estimated by the
Kaplan-Meier method and compared by using the log-rank test.
* P,0.05 vs. Vehicle.
doi:10.1371/journal.pone.0002026.g007
Figure 8. Alterations in intestinal (A) and pulmonary (B) MPO activities, and serum levels of lactate (C) in sham-operated animals
(Sham) and ischemia/reperfusion animals treated with normal saline (Vehicle) or [D-Arg
1 D-Phe
5 D-Trp
7, 9 Leu
11]-substance P (GA
antagonist) at 1.5 h after the completion of treatment (i.e., 2 h after reperfusion). Data are presented as means6SE (n=5–6) and
compared by one-way ANOVA and Student-Newman-Keuls test: * P,0.05 versus Sham group; # P,0.05 versus Vehicle group. Alterations in the
survival rate (D) at 10 days after gut ischemia/reperfusion with normal saline treatment (Vehicle) and gut ischemia/reperfusion with [D-Arg
1 D-Phe
5
D-Trp
7, 9 Leu
11]-substance P (GA antagonist). There were 12 animals in each group. Survival rate in the vehicle treated animals is derived from Figure 7.
The survival rate was estimated by the Kaplan-Meier method and compared by using the log-rank test. * P,0.05 vs. Vehicle.
doi:10.1371/journal.pone.0002026.g008
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protective after gut I/R
To further confirm that ghrelin’s beneficial effects after gut I/R
are mediated through the central nervous system, ICV adminis-
tration of ghrelin was performed at the beginning of reperfusion
after 90-min gut ischemia. As shown in Figures 10A–B, ICV
injection of ghrelin significantly inhibits TNF-a release (P,0.05,
Fig. 10A), reduces serum levels of lactate (P,0.05, Fig. 10B).
Similarly, ICV injection of ghrelin also decreases neutrophil
infiltration in the gut (P,0.05, Fig. 10C) and ameliorates intestinal
barrier dysfunction (P,0.05, Fig. 10D).
Discussion
Gut I/R injury is a serious condition in intensive care patients.
Activation of immune cells adjacent to the huge endothelial cell
surface area of the intestinal microvasculature produces initially
local and then systemic inflammatory responses. Balanced
inflammatory responses are essential elements of a successful host
response after injury. However, excessive and sustained inflam-
matory responses can lead to severe tissue damage. Using an
established animal model of gut I/R (i.e., superior mesenteric
artery occlusion), the present study shows that plasma levels of
ghrelin are significantly reduced after gut I/R. Therefore, there is
a ghrelin deficiency after gut I/R. Ghrelin is a novel gastrointes-
tinal hormone. The biological effects of ghrelin are mediated
through the ghrelin receptor (i.e., GHSR-1a), a 7 transmembrane
domain Gq protein coupled receptor [7,17]. Ghrelin is the only
identified endogenous ligand for this receptor. Ghrelin was
originally reported to induce growth hormone release through
pituitary GHSR-1a stimulation [9,18,19]. However, a large body
of evidence has indicated other physiological functions of ghrelin
Figure 9. Effects of vagotyomy on serum levels of TNF-a (A) and lactate (B), intestinal MPO activities (C), and intestinal mucosal
permeability (D) to fluorescein isothiocyanate dextran with a molecular weight of 4000 Da (FD4) in sham-operated animals (Sham)
and ischemia/reperfusion animals treated with normal saline (Vehicle) or ghrelin (Ghrelin) at 1.5 h after the completion of
treatment (i.e., 2 h after reperfusion). Data are expressed as means6SE (n=6–7/group) and compared by one-way analysis of variance (ANOVA)
and Student-Newman-Keuls test: *P,0.05 versus sham-operated animals.
doi:10.1371/journal.pone.0002026.g009
Figure 10. Alterations in serum levels of TNF-a (A) and lactate (B), intestinal MPO activities (C), and intestinal mucosal permeability
(D) to fluorescein isothiocyanate dextran with a molecular weight of 4000 Da (FD4) in sham-operated animals (Sham) and
ischemia/reperfusion animals treated with intracerebroventricular (ICV) injection of normal saline (Vehicle) or ghrelin (Ghrelin) at
1.5 h after the completion of treatment (i.e., 2 h after reperfusion). Data are presented as means6SE (n=6) and compared by one-way
ANOVA and Student-Newman-Keuls test: * P,0.05 versus Sham group; # P,0.05 versus Vehicle group.
doi:10.1371/journal.pone.0002026.g010
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GHSR-1a is found in the brain stem, pituitary, hypothalamus,
heart, blood vessels, lungs, stomach, pancreas, intestines, kidneys,
and adipose tissue [20–22]. The wide distribution of GHSR-1a
suggests multiple paracrine, autocrine and endocrine roles of
ghrelin [20–23]. It has been linked to the regulation of pituitary
hormone secretion, feeding, energy homeostasis, gastrointestinal
function, and cardiovascular and immune system [14,24,25].
Since administration of a specific ghrelin receptor antagonist
increases proinflammatory cytokine release in normal animals
[26,27], the acute ghrelin deficiency after gut I/R may contribute
to local and systemic inflammatory derangements under such
conditions. The result, that the ghrelin receptor antagonist
worsens gut I/R-induced organ injury and mortality, further
confirms the important role of ghrelin deficiency in gut I/R injury.
Our current results also show that ghrelin administration
inhibits proinflammatory cytokine release, reduces neutrophil
infiltration, ameliorates intestinal barrier dysfunction, attenuates
organ injury, and improves survival after gut I/R. However,
ghrelin’s direct effect on inflammatory cytokine release from
macrophages is negligible [14]. It has been reported that ghrelin
activates the vagus nerve and vagal blockade abolishes ghrelin-
induced feeding and growth hormone secretion [28]. The current
study also indicates that the protection of ghrelin after gut I/R
requires the intact vagus nerve, as vagotomy prevents its beneficial
effects. Ghrelin can cross the blood-brain barrier [29–31]. Since
ICV injection of ghrelin is also protective after gut I/R, it appears
that the stimulatory effect of ghrelin on the vagus nerve is mainly
mediated via the central nervous system. This is not surprising,
because ghrelin receptors are expressed at a high density in the
brain [22,32]. Stimulation of the vagus nerve can rapidly attenuate
systemic inflammatory responses through inhibiting the activation
of macrophages and endothelial cells. This physiological mecha-
nism, termed ‘the cholinergic anti-inflammatory pathway’, can
reflexively monitor and adjust the inflammatory response to
prevent excessive inflammation. This pathway has major implica-
tions in immunology; however, the endogenous molecule(s) for the
regulation of this pathway remains unknown. Our current findings
strongly suggest that ghrelin may be the circulating mediator for
the link between the vagus nerve and the immune system.
An underlying defect in the activity of the cholinergic anti-
inflammatory pathway may trigger an overwhelming and self-
destructive immune response to an otherwise innocuous immu-
nological stimulus and thus contribute to disease pathogenesis
[3,33]. Abundant evidence points to the concept that complex
behavior originating in higher brain centers can directly influence
outflow through the vagus nerve. Sudden death, increased
morbidity and mortality following cardiac surgery in hostile or
depressed patients, and increased death rates in patients with
sepsis or organ failure can be linked clinically to decreased vagus
nerve activity [34–38]. Although it is not currently known whether
vagus nerve activity in the heart correlates with the activation of
the cholinergic anti-inflammatory pathway, there have been
reports of decreased cardiac vagus nerve activity in diseases
associated with exaggerated inflammatory responses [33]. Clinical
observations implicate a significant correlation between decreased
instantaneous heart rate variability and increased morbidity and/
or mortality in sepsis, rheumatoid arthritis, lupus, sarcoidosis,
inflammatory bowel diseases, and trauma [39–42]. Thus,
decreased circulating levels of ghrelin after gut I/R may impair
the efficacy of the cholinergic anti-inflammatory pathway, thereby
leading to the hyper-inflammatory state and subsequent local and
remote organ injuries. These findings also suggest that adminis-
tration of ghrelin after gut I/R attenuates excessive inflammation
and reduces organ injury through the rapid activation of the
cholinergic anti-inflammatory pathway. In this regard, ghrelin
may be the therapeutic agent in various inflammatory disorders
such as sepsis, hemorrhagic shock, and inflammatory bowel
disease characterized by an overwhelming inflammatory response.
Materials and Methods
Animal model of gut ischemia/reperfusion
Male Sprague-Dawley rats (275–325g) were housed in a
temperature-controlled room on a 12-h light/dark cycle and fed
a standard Purina rat chow diet. Prior to the induction of
ischemia, rats were fasted overnight but allowed water ad libitum.
Rats were anesthetized with isoflurane inhalation and the ventral
neck, abdomen and groin were shaved and washed with 10%
povidone iodine. A catheter (PE-50 tubing) was placed in the
femoral vein after carefully separating the femoral nerve and blood
vessels. A 2-cm midline abdominal incision was performed. A
microvascular clip was placed across the superior mesenteric
artery (SMA) for 90 min. The microvascular clip was then
removed to allow reperfusion, and the animals were randomly
assigned to various groups. Sham animals (i.e., control animals)
underwent the same surgical procedure with the exception of the
SMA clamping. All experiments were performed in accordance
with the National Institutes of Health guidelines for the use of
experimental animals. This project was approved by the
Institutional Animal Care and Use Committee of the Feinstein
Institute for Medical Research.
Intravenous administration of ghrelin
Immediately after removing the microvascular clip, ghrelin
(12 nmol/kg BW, Phoenix Pharmaceuticals, Belmont, CA), or
vehicle (1-ml normal saline) was administered intravenously over a
period of 30 min through a pump (Harvard Apparatus, Holliston,
MA). Animals were then anesthetized at 2 h after reperfusion (i.e.,
1.5 h after the completion of treatment) or sham operation for
collection of blood and tissue samples.
Determination of plasma levels of ghrelin, TNF-a and IL-6
Plasma levels of ghrelin, TNF-a and IL-6 were quantified using
an enzyme-linked immunosorbent assay (ELISA) kit specifically for
ghrelin (Linco Research, Inc, St. Charles, MO), rat TNF-a or IL-6
(BD Biosciences, San Diego, CA). The assay was carried out
according to the instructions provided by the manufacturer.
Granulocyte myeloperoxidase assessment
Neutrophil accumulation within the gut and lung tissue was
estimated using the MPO activity assay as we described previously
[43].
Water content determination and histological
examination
Gut and lung edema were estimated by comparing tissue water
content. Briefly, gut and lung tissues were dried in a 70uC oven for
48 h. Gut and lung water content was calculated as %
H2O=(12dry wt/wet wt) 6 100%. The morphological alter-
ations in the gut and lungs were examined by hematoxylin and
eosin (H-E) staining.
Determination of intestinal mucosal permeability
Intestinal barrier function was assessed by measuring translo-
cation of the fluorescent tracer, fluorescein isothiocyanate dextran
with a molecular weight of 4000 Da (FD4, Sigma) by the everted
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used by us [48].
Determination of bacterial translocation
The mesenteric lymph nodes complex was harvested and equal
amount of wet tissues was homogenized and briefly centrifuged to
remove gross particulate matters. Serial log dilutions of tissue
homogenates were applied. Five hundred ml of each dilution was
then plated on chocolate agar plates (Fisher Scientific) and
incubated at 37uC for 24 h under aerobic conditions. The
colony-forming units (CFU) were counted and results were
expressed as CFU per gram of tissue.
Determination of serum levels of lactate
Serum concentrations of lactate were determined by using an
assay kit according to the manufacturer’s instructions (Pointe
Scientific, Lincoln Park, MI).
Survival Study
In additional groups of animals, ghrelin (12 nmol/kg BW), or
vehicle (1-ml normal saline) was administered intravenously over a
period of 30 min to animals that underwent 90 min gut ischemia
immediately after removing the microvascular clip as described
above. The animals were then allowed food and water ad libitum
and were monitored for 10 days to record survival.
Administration of ghrelin receptor antagonist [D-Arg
1 D-
Phe
5 D-Trp
7, 9 Leu
11]-substance P
To further define the role of ghrelin deficiency in gut I/R
injury, a specific and potent ghrelin receptor antagonist, [D-Arg
1
D-Phe
5 D-Trp
7, 9 Leu
11]-substance P (Bachem, Torrance, CA)
[49], was administered to intestinal I/R animals. Briefly,
immediately after removing the microvascular clip, [D-Arg
1 D-
Phe
5 D-Trp
7, 9 Leu
11]-substance P (0.2 mmol/kg BW in 1 ml
normal saline) was administered intravenously over a period of
30 min through a pump. Serum levels of lactate, gut and lung
MPO activity were determined at 2 h after reperfusion (i.e., 1.5 h
after [D-Arg
1 D-Phe
5 D-Trp
7, 9 Leu
11]-substance P administra-
tion) or sham operation. In additional groups of animals, survival
was recorded for 10 days thereafter.
Vagotomy
The dorsal and ventral branches of the vagus nerve were
dissected from the esophagus as we described recently [14]. Gut
ischemia was then performed by SMA occlusion for 90 min. At
the end of 90 min gut ischemia or sham operation, ghrelin or
vehicle was administrated intravenously as described above in the
vagus nerve intact animals. At 1.5 h after the completion of
treatment or sham operation (i.e., 3.5 h after vagotomy), serum
levels of TNF-a were measured by ELISA. Neutrophil infiltration
in the gut was assessed by determining intestinal MPO activity.
Organ injury was evaluated by measuring ileal mucosal perme-
ability to FD4 and serum lactate levels.
Intracerebroventricular (ICV) injection of ghrelin
To further confirm that ghrelin’s beneficial effects after gut I/R
are mediated through the central nervous system, ICV adminis-
tration of ghrelin (1 nmol in 10 ml) was performed at the beginning
of reperfusion after 90-min gut ischemia as we described recently
[26]. At 2 h after reperfusion, serum levels of TNF-a were
measured by ELISA. Neutrophil infiltration in the gut was assessed
by determining MPO activity. Organ injury was evaluated by
measuring ileal mucosal permeability to FD4 and serum lactate
levels. The location of ICV injections was confirmed by
histological examination of the brain after the experiment.
Statistical analysis
All data are expressed as mean6standard error (SE) and
compared by one-way analysis of variance (ANOVA) and Student-
Newman-Keuls test for multiple group analysis. The survival rate
was estimated by Kaplan-Meier method and compared by the log-
rank test. Differences in values were considered significant if
P,0.05.
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